Business Context and Reporting Period
This Form 6-K is filed by FSD Pharma Inc. (a foreign private issuer) for the month of December 2021. The report was signed on December 3, 2021, by Nathan Coyle, Chief Financial Officer. The registrant files annual reports under Form 40-F.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a notification of a press release rather than a financial statement.
Material Changes
No material financial changes versus the prior comparable period are disclosed in this filing.
Guidance, Outlook, and Management Commentary
The primary content of this filing is the announcement that FSD Pharma will present at the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6, 2021. No specific financial guidance, risk factors, or contingencies are detailed in the provided text.
Investor Verification Checklist
- Verify the date and agenda of the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference presentation.
- Review the full press release (Exhibit 99.1) for any additional operational updates not summarized in the Form 6-K header.
- Confirm the company's latest financial position by referencing the most recent Form 40-F or quarterly reports, as this filing contains no financial data.